MCID: ADR013
MIFTS: 54

Adrenal Gland Hyperfunction

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Hyperfunction

MalaCards integrated aliases for Adrenal Gland Hyperfunction:

Name: Adrenal Gland Hyperfunction 12 76 53 15 73
Hypercortisolism 12 54 29 55
Hyperadrenalism 12 76 53
Adrenocortical Hyperfunction 12 44
Cushing Syndrome 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3947
MeSH 44 D000308
NCIt 50 C113208
UMLS 73 C0001622

Summaries for Adrenal Gland Hyperfunction

NINDS : 54 Cushing's syndrome, also called hypercortisolism, is a rare endocrine disorder caused by chronic exposure of the body's tissues to excess levels of cortisol - a hormone naturally produced by the adrenal gland. Exposure to too much cortisol can occur from long-term use of synthetic glucocorticoid hormones to treat inflammatory illnesses. Pituitary adenomas (benign tumors of the pituitary gland) that secrete increased amounts of ACTH (adrenocorticotropic hormone, a substance that controls the release of cortisol) can also spur overproduction of cortisol. Tumors of the adrenal gland and ectopic ACTH syndrome (a condition in which ACTH is produced by various types of potentially malignant tumors that occur in different parts of the body) can cause similar problems with cortisol balance. Common symptoms of Cushing's syndrome include upper body obesity, severe fatigue and muscle weakness, high blood pressure, backache, elevated blood sugar, easy bruising, and bluish-red stretch marks on the skin. In women, there may be increased growth of facial and body hair, and menstrual periods may become irregular or stop completely. Neurological symptoms include difficulties with memory and neuromuscular disorders.

MalaCards based summary : Adrenal Gland Hyperfunction, also known as hypercortisolism, is related to apparent mineralocorticoid excess and acth-secreting pituitary adenoma, and has symptoms including cushingoid facies An important gene associated with Adrenal Gland Hyperfunction is POMC (Proopiomelanocortin), and among its related pathways/superpathways are G-Beta Gamma Signaling and Peptide ligand-binding receptors. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, pituitary and testes, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Wikipedia : 76 Adrenocortical hyperfunction is a condition where there is an overexpression of products of the adrenal... more...

Related Diseases for Adrenal Gland Hyperfunction

Diseases related to Adrenal Gland Hyperfunction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 apparent mineralocorticoid excess 32.5 NR3C1 NR3C2 POMC
2 acth-secreting pituitary adenoma 32.3 CRH NR3C1 POMC PRL
3 conn's syndrome 32.0 CRH CYP21A2 NR3C1 NR3C2 POMC PRKAR1A
4 hypoadrenalism 30.6 CRH GH1 POMC
5 bronchus adenoma 10.9 POMC SST
6 acidophil adenoma 10.8 POMC SST
7 allergic urticaria 10.7 CRH NR3C1
8 acute adrenal insufficiency 10.7 CYP21A2 POMC
9 cytochrome p450 oxidoreductase deficiency 10.7 CYP21A2 POMC
10 acth deficiency, isolated 10.7 CRH POMC
11 hormone producing pituitary cancer 10.7 PRKAR1A SST
12 pituitary apoplexy 10.6 POMC PRL
13 mental depression 10.6 CRH NR3C1 POMC
14 primary pigmented nodular adrenocortical disease 10.6 NR3C1 POMC PRKAR1A
15 sheehan syndrome 10.6 CRH POMC PRL
16 corticosteroid-binding globulin deficiency 10.6 NR3C1 POMC SERPINA6
17 chronic fatigue syndrome 10.6 CRH NR3C1 POMC
18 prolactin producing pituitary tumor 10.6 PRL SST
19 fibrous dysplasia/mccune-albright syndrome 10.6 GH1 PRL
20 premenstrual tension 10.5 CRH POMC PRL
21 lymphocytic hypophysitis 10.5 GH1 POMC
22 pituitary infarct 10.5 POMC PRL SST
23 chiasmal syndrome 10.5 POMC PRL SST
24 adrenal cortical hypofunction 10.5 CRH CYP21A2 POMC
25 hypoadrenocorticism, familial 10.5 CRH CYP21A2 POMC
26 melancholia 10.5 CRH PRL
27 diabetes insipidus 10.5 CRH POMC PRL
28 hyperaldosteronism, familial, type i 10.5 NR3C1 NR3C2 POMC
29 organ system benign neoplasm 10.5 POMC PRL SST
30 adrenal carcinoma 10.5 CRH CYP21A2 POMC
31 non-functioning pituitary adenoma 10.5 GH1 SST
32 mood disorder 10.5 CRH NR3C1 POMC
33 growth hormone secreting pituitary adenoma 10.5 PRKAR1A PRL SST
34 cell type benign neoplasm 10.5 POMC PRL SST
35 multiple endocrine neoplasia, type iv 10.5 PRKAR1A PRL
36 testicular leydig cell tumor 10.4 CYP21A2 POMC
37 sex differentiation disease 10.4 CYP21A2 POMC PRL
38 pseudohypoparathyroidism, type ia 10.4 GH1 PRL
39 adrenocortical carcinoma, hereditary 10.4 CYP21A2 POMC PRKAR1A
40 hyperandrogenism 10.4 CYP21A2 POMC PRL
41 gonadal disease 10.4 CRH GH1 POMC
42 steroid inherited metabolic disorder 10.3 CYP21A2 POMC
43 adenohypophysitis 10.3 GH1 POMC PRL
44 empty sella syndrome 10.3 GH1 POMC PRL
45 hypothyroidism, congenital, nongoitrous, 4 10.3 GH1 POMC PRL
46 pylorospasm 10.3 GHRL SST
47 glucagonoma 10.3 GHRH SST
48 pituitary hormone deficiency, combined, 2 10.3 GH1 POMC PRL
49 pituitary carcinoma 10.3 CRH POMC PRL SST
50 tsh producing pituitary tumor 10.3 GH1 PRL SST

Graphical network of the top 20 diseases related to Adrenal Gland Hyperfunction:



Diseases related to Adrenal Gland Hyperfunction

Symptoms & Phenotypes for Adrenal Gland Hyperfunction

UMLS symptoms related to Adrenal Gland Hyperfunction:


cushingoid facies

GenomeRNAi Phenotypes related to Adrenal Gland Hyperfunction according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CYP21A2 GHRL GIPR NR3C1 NR3C2 POMC

MGI Mouse Phenotypes related to Adrenal Gland Hyperfunction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 SERPINA6 NR3C1 CRH NR3C2 POMC GHRL
2 homeostasis/metabolism MP:0005376 10.03 SERPINA6 NR3C1 CRH NR3C2 POMC GHRH
3 endocrine/exocrine gland MP:0005379 9.97 NR3C1 CRH POMC GHRH GHRL PRKAR1A
4 adipose tissue MP:0005375 9.88 NR3C1 CRH POMC GHRL PRKAR1A LEP
5 immune system MP:0005387 9.81 PRL SERPINA6 NR3C1 CRH GHRH POMC
6 liver/biliary system MP:0005370 9.56 SERPINA6 NR3C1 CRH POMC GHRH PRKAR1A
7 renal/urinary system MP:0005367 9.1 LEP NR3C1 NR3C2 CRH POMC SERPINA6

Drugs & Therapeutics for Adrenal Gland Hyperfunction

Drugs for Adrenal Gland Hyperfunction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-43-4 5816
2
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 329-65-7 838
3
Eplerenone Approved Phase 4,Not Applicable 107724-20-9 150310 443872
4
Spironolactone Approved Phase 4,Not Applicable 1952-01-7, 52-01-7 5833
5
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Captopril Approved Phase 4 62571-86-2 44093
8
Mifepristone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 84371-65-3 55245
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
12
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
13
Losartan Approved Phase 4 114798-26-4 3961
14 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Mydriatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 diuretics Phase 4,Not Applicable
28 Diuretics, Potassium Sparing Phase 4,Not Applicable
29 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3,Not Applicable
33 Mineralocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
34 Natriuretic Agents Phase 4,Not Applicable
35 Antiparkinson Agents Phase 4
36 Dopamine Agents Phase 4
37 Dopamine agonists Phase 4
38 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Angiotensin-Converting Enzyme Inhibitors Phase 4
40 Antihypertensive Agents Phase 4,Phase 3,Not Applicable
41 HIV Protease Inhibitors Phase 4,Phase 2,Not Applicable
42
protease inhibitors Phase 4,Phase 2,Not Applicable
43 Contraceptive Agents Phase 4,Phase 3,Phase 1,Phase 2
44 Contraceptives, Oral Phase 4,Phase 3,Phase 1,Phase 2
45 Contraceptives, Postcoital Phase 4,Phase 3,Phase 1,Phase 2
46 Luteolytic Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Analgesics Phase 4
48 Analgesics, Non-Narcotic Phase 4
49 Analgesics, Opioid Phase 4
50 Antipyretics Phase 4

Interventional clinical trials:

(show top 50) (show all 161)
# Name Status NCT ID Phase Drugs
1 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
2 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4 Eplerenone;Placebo
3 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
4 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4 Mifepristone
5 Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia. Completed NCT02198378 Phase 4 MEOPA and paracetamol;Morphine
6 Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism Completed NCT00155064 Phase 4 captopril, Losartan (drug)
7 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
8 Prevention of Metabolic Complications of Glucocorticoid Excess Unknown status NCT01319994 Phase 2, Phase 3 Metformin;Placebo
9 COrticosteroid in Congenital Adrenal Hyperplasia Unknown status NCT02552251 Phase 2, Phase 3
10 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
11 Effects of IL-1 Beta on the HPA-axis in Obese Persons Completed NCT02227420 Phase 3 Anakinra
12 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
13 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
14 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
15 SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. Completed NCT01096654 Phase 3
16 The Role of Mineralocorticoid Receptors in Vascular Function Completed NCT00759525 Phase 2, Phase 3 Glycyrrhetic Acid;Placebo
17 A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. Recruiting NCT03277690 Phase 3 Levoketoconazole;Placebo
18 Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome Recruiting NCT02297945 Phase 3 metyrapone
19 A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Recruiting NCT03062280 Phase 3 Hydrocortisone
20 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Recruiting NCT02716818 Phase 3 Chronocort®;standard glucocorticoid therapy
21 Adrenal Artery Ablation Treats Primary Aldosteronism Recruiting NCT03398785 Phase 3
22 Treatment for Endogenous Cushing's Syndrome Active, not recruiting NCT01838551 Phase 3 COR-003
23 Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy Not yet recruiting NCT03532022 Phase 3 Chronocort®;Standard Care
24 Mifepristone for Metabolic Syndrome Completed NCT01419535 Phase 1, Phase 2 Mifepristone
25 Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism Completed NCT00732771 Phase 2 LCI699
26 A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia Completed NCT02804178 Phase 2 ATR-101
27 Dexamethasone Treatment of Congenital Adrenal Hyperplasia Completed NCT00621985 Phase 2 dexamethasone;Hydrocortisone
28 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia Completed NCT00519818 Phase 1, Phase 2 Chronocort;Cortef
29 Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets Completed NCT00000102 Phase 1, Phase 2 Nifedipine
30 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia Completed NCT01859312 Phase 2 Hydrocortisone (Solucortef)
31 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH Completed NCT01735617 Phase 2 Hydrocortisone Modified Release Capsules
32 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
33 Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome Recruiting NCT02019706 Phase 2 F-DOPA PET Scan;Mifepristone;Ga-DOTATATE;Octreoscan
34 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Recruiting NCT00001849 Phase 1, Phase 2 Pentetreotide;18-F-fluorodeoxyglucose;(18F)-L-3,4-dihydroxyophenylalanine (18F-DOPA)
35 Open-label Study on Treatment of Primary Aldosteronism With Everolimus Recruiting NCT03174171 Phase 2 Everolimus 0.75 mg
36 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia Recruiting NCT03525886 Phase 2 NBI-74788
37 Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia Recruiting NCT03257462 Phase 2 SPR001
38 Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia Recruiting NCT01771328 Phase 2 Hydrocortisone;Cortisone acetate
39 Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia Recruiting NCT02096510 Phase 1, Phase 2 Solu-Cortef;Cortef
40 A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome Recruiting NCT03053271 Phase 2 ATR-101;Placebos
41 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
42 Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs Recruiting NCT02611258 Phase 2 Tadalafil
43 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
44 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Active, not recruiting NCT02804750 Phase 2 CORT125134
45 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
46 Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy Active, not recruiting NCT01867710 Phase 2 Abiraterone Acetate;Prednisone 5 mg twice daily;Prednisone 5 mg once daily;Prednisone 2.5 mg twice daily;Dexamethasone 0.5 mg once daily
47 Androgen Reduction in Congenital Adrenal Hyperplasia Not yet recruiting NCT03548246 Phase 2 Abiraterone acetate;Placebo;Hydrocortisone;Fludrocortisone
48 Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
49 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
50 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone

Search NIH Clinical Center for Adrenal Gland Hyperfunction

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: adrenocortical hyperfunction

Genetic Tests for Adrenal Gland Hyperfunction

Genetic tests related to Adrenal Gland Hyperfunction:

# Genetic test Affiliating Genes
1 Hypercortisolism 29

Anatomical Context for Adrenal Gland Hyperfunction

MalaCards organs/tissues related to Adrenal Gland Hyperfunction:

41
Adrenal Gland, Pituitary, Testes, Cortex, Adrenal Cortex, Skin, Bone

Publications for Adrenal Gland Hyperfunction

Articles related to Adrenal Gland Hyperfunction:

(show top 50) (show all 151)
# Title Authors Year
1
Severe Cushing Syndrome Due to an ACTH-Producing Pheochromocytoma: A Case Presentation and Review of the Literature. ( 29942926 )
2018
2
Two types of ectopic Cushing syndrome or a continuum? Review. ( 29766359 )
2018
3
UTILITY OF A SINGLE LATE-NIGHT PLASMA CORTISOL AND ACTH FOR THE DIAGNOSIS OF CUSHING SYNDROME. ( 29144801 )
2018
4
Combined Ovarian and Adrenal Venous Sampling in the Localization of Adrenocorticotropic Hormone-Independent Ectopic Cushing Syndrome. ( 29161416 )
2018
5
Familial Forms of Cushing Syndrome in Primary Pigmented Nodular Adrenocortical Disease Presenting with Short Stature and Insidious Symptoms: A Clinical Series. ( 29909407 )
2018
6
Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome. ( 29094256 )
2018
7
Cushing syndrome due to adrenal carcinoma. ( 29633121 )
2018
8
Ectopic Cushing syndrome: Report of 9 cases. ( 29655957 )
2018
9
Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome. ( 29264446 )
2017
10
Ectopic Cushing syndrome in small cell lung cancer: A case report and literature review. ( 28102935 )
2017
11
Adrenal Oncocytoma - A Rare Functional Tumor Presenting as Cushing Syndrome. ( 29327532 )
2017
12
ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA. ( 28614007 )
2017
13
Three-Quarters Adrenalectomy for Infantile-Onset Cushing Syndrome due to Bilateral Adrenal Hyperplasia in McCune-Albright Syndrome. ( 28528327 )
2017
14
Successful percutaneous CT-guided microwave ablation of adrenal gland for ectopic Cushing syndrome. ( 27919009 )
2017
15
Diurnal Plasma Cortisol Measurements Utility in Differentiating Various Etiologies of Endogenous Cushing Syndrome. ( 27643448 )
2016
16
Chronic central serous chorioretinopathy as a presenting symptom of Cushing syndrome. ( 27135093 )
2016
17
Small cell carcinoma of the prostate presenting with Cushing Syndrome. A narrative review of an uncommon condition. ( 27068390 )
2016
18
Ectopic Cushing syndrome due to neuroendocrine prostatic cancer. ( 27170243 )
2016
19
Cushing Syndrome Due to ACTH-Secreting Pheochromocytoma, Aggravated by Glucocorticoid-Driven Positive-Feedback Loop. ( 26700559 )
2016
20
Ectopic Cushing syndrome secondary to recurrent pancreatoblastoma in a child: Lessons learnt. ( 26881602 )
2015
21
Bilateral symmetrical adrenal hypermetabolism on FDG PET/CT due to Cushing syndrome in well differentiated neuroendocrine carcinoma. ( 26522002 )
2015
22
Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes. ( 25449630 )
2015
23
Positive (68)Ga-DOTATOC-PET/CT after cortisol level control during ketoconazole treatment in a patient with liver metastases from a pancreatic neuroendocrine tumor and ectopic Cushing syndrome. ( 25168486 )
2015
24
RETRACTED ARTICLE: Fatal factitious Cushing syndrome (MA1nchhausen's syndrome) in a patient with macroprolactinoma and silent corticotrophinoma: case report and literature review. ( 28702222 )
2015
25
ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature. ( 25353285 )
2015
26
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion from a Meckel diverticulum neuroendocrine tumor: case report. ( 26610855 )
2015
27
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome. ( 26331322 )
2015
28
PET imaging in ectopic Cushing syndrome: a systematic review. ( 26206753 )
2015
29
The first description of metyrapone use in severe Cushing Syndrome due to ectopic ACTH secretion in an infant with immature sacrococcygeal teratoma. Case Report. ( 26859587 )
2015
30
Skeletal Maturation in Children with Cushing Syndrome Is Not Consistently Delayed: The Role of Corticotropin, Obesity, and Steroid Hormones, and the Effect of Surgical Cure. ( 24412141 )
2014
31
Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes. ( 24859505 )
2014
32
Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. ( 25513635 )
2014
33
Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. ( 23778239 )
2014
34
A case of iatrogenic Cushing syndrome and apparent mineralocorticoid excess presenting with accelerated hypertension and proteinuria. ( 25201428 )
2014
35
Late-onset congenital adrenal hyperplasia with Cushing syndrome. ( 25175129 )
2014
36
Exogenous Cushing Syndrome: A Lesson of Diaper Rash Cream. ( 25300899 )
2014
37
Differences in adiposity in Cushing syndrome caused by PRKAR1A mutations: clues for the role of cyclic AMP signaling in obesity and diagnostic implications. ( 24248186 )
2014
38
Open-angle glaucoma secondary to Cushing syndrome related to an adrenal adenoma: Case report. ( 25264153 )
2014
39
Cushing syndrome secondary to CRH-producing Wilms tumor in a 6 year old. ( 25153573 )
2014
40
Erratum: Concomitant Takayasu arteritis and Cushing syndrome in a child undergoing open adrenalectomy: An anaesthetic challenge: Corrigendum. ( 25533383 )
2014
41
Ectopic Cushing syndrome associated with thymic carcinoid tumor as the first presentation of MEN1 syndrome-report of a family with MEN1 gene mutation. ( 24218143 )
2014
42
Bilateral posterior retroperitoneal robotic adrenalectomy for ACTH-independent Cushing syndrome. ( 24710229 )
2014
43
Aldosterone- and cortisol-co-producing adrenal adenoma without clinical features of Cushing syndrome. ( 25228847 )
2014
44
Carney complex: a rare cause of Cushing syndrome in pregnancy. ( 25004313 )
2014
45
A challenging case of an ectopic cushing syndrome. ( 25431598 )
2014
46
Tumor localization in ectopic Cushing syndrome using combined PET/CT imaging. ( 23816940 )
2013
47
Adrenocorticotropic hormone-independent cushing syndrome with bilateral cortisol-secreting adenomas. ( 24396667 )
2013
48
Severe ectopic cushing syndrome caused by adenoid cystic carcinoma of a salivary gland. ( 23757606 )
2013
49
Topical-steroid-induced iatrogenic Cushing syndrome in the pediatric age group: A rare case report. ( 24251179 )
2013
50
Cushing syndrome and rebound generalized pustular psoriasis from Chinese herbs. ( 23855684 )
2013

Variations for Adrenal Gland Hyperfunction

Expression for Adrenal Gland Hyperfunction

Search GEO for disease gene expression data for Adrenal Gland Hyperfunction.

Pathways for Adrenal Gland Hyperfunction

Pathways related to Adrenal Gland Hyperfunction according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.74 CRH GH1 GHRH POMC PRKAR1A
2
Show member pathways
12.59 CRH GH1 GHRH GHRL GIPR LEP
3
Show member pathways
12.19 GH1 LEP NR3C1 PRL
5 11.91 NR3C1 PRKAR1A SST
6
Show member pathways
11.82 GH1 GHRL LEP POMC
7 11.79 GH1 LEP NR3C1
8 11.62 CRH GHRH GIPR POMC
9 11.6 CRH CYP21A2 POMC
10 11.17 BGLAP NR3C1 POMC PRL
11 10.85 LEP NR3C1
12 10.4 NR3C1 SERPINA6
13 10.21 CRH POMC

GO Terms for Adrenal Gland Hyperfunction

Cellular components related to Adrenal Gland Hyperfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 BGLAP CRH GH1 GHRH GHRL LEP
2 extracellular space GO:0005615 9.32 BGLAP CRH GH1 GHRH GHRL LEP
3 endosome lumen GO:0031904 9.16 GH1 PRL

Biological processes related to Adrenal Gland Hyperfunction according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.77 BGLAP CRH LEP
2 female pregnancy GO:0007565 9.74 CRH LEP PRL
3 response to nutrient GO:0007584 9.7 GIPR LEP SST
4 response to estrogen GO:0043627 9.65 BGLAP CRH GHRL
5 positive regulation of cAMP-mediated signaling GO:0043950 9.61 CRH GIPR
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 GH1 PRL
7 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.58 GH1 GHRH
8 positive regulation of growth GO:0045927 9.56 GH1 GHRL
9 adult feeding behavior GO:0008343 9.55 GHRL LEP
10 glucocorticoid biosynthetic process GO:0006704 9.54 CRH CYP21A2
11 positive regulation of growth hormone secretion GO:0060124 9.51 GHRH GHRL
12 positive regulation of multicellular organism growth GO:0040018 9.5 GH1 GHRH GHRL
13 regulation of signaling receptor activity GO:0010469 9.5 GH1 GHRH GHRL LEP POMC PRL
14 growth hormone secretion GO:0030252 9.49 GHRH GHRL
15 hormone-mediated apoptotic signaling pathway GO:0008628 9.46 CRH SST
16 positive regulation of corticotropin secretion GO:0051461 9.43 CRH GHRL
17 positive regulation of cortisol secretion GO:0051464 9.4 CRH GHRL
18 negative regulation of glucagon secretion GO:0070093 9.37 CRH LEP
19 positive regulation of JAK-STAT cascade GO:0046427 9.33 GH1 LEP PRL
20 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.26 CRH GHRL
21 response to nutrient levels GO:0031667 9.02 BGLAP GH1 GHRL LEP PRL
22 G-protein coupled receptor signaling pathway GO:0007186 10.07 CRH GHRH GHRL GIPR POMC SST

Molecular functions related to Adrenal Gland Hyperfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.62 CYP21A2 NR3C1 NR3C2 SERPINA6
2 prolactin receptor binding GO:0005148 9.26 GH1 PRL
3 steroid binding GO:0005496 9.26 CYP21A2 NR3C1 NR3C2 SERPINA6
4 hormone activity GO:0005179 9.17 CRH GH1 GHRL LEP POMC PRL
5 growth hormone-releasing hormone activity GO:0016608 9.16 GHRH GHRL

Sources for Adrenal Gland Hyperfunction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....